Recently, the Category 1 innovative drug Tunlametinib Capsules (Chinese trade name: 科露平) of Shanghai KeChow Pharmaceuticals Co. Ltd was approved with conditions for marketing by the National Medical Products Administration with priority review and approval, which is applicable to patients with advanced melanoma containing anti-PD-1/PD-L1 treatment failure of the NRAS mutation.

Tunlametinib is a selective mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor that exerts antitumor effects by inhibiting MEK1/2 kinase activity. The marketing of this drug provides a new treatment option for patients with advanced melanoma containing anti-PD-1/PD-L1 treatment failure of the NRAS mutation.